Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer

OBJECTIVE: The mitochondrial pyruvate carrier (MPC) has emerged as a promising drug target for metabolic disorders, including non-alcoholic steatohepatitis and diabetes, metabolically dependent cancers and neurodegenerative diseases. A range of structurally diverse small molecule inhibitors have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavoulari, Sotiria, Schirris, Tom J.J., Mavridou, Vasiliki, Thangaratnarajah, Chancievan, King, Martin S., Jones, Daniel T.D., Ding, Shujing, Fearnley, Ian M., Kunji, Edmund R.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968063/
https://www.ncbi.nlm.nih.gov/pubmed/35278701
http://dx.doi.org/10.1016/j.molmet.2022.101469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968063/
https://www.ncbi.nlm.nih.gov/pubmed/35278701
http://dx.doi.org/10.1016/j.molmet.2022.101469

Ejemplares similares